Spectra Laboratories (select assets from Fresenius Medical Care)
2025
Why
Quest acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories to expand renal-specific testing capabilities for dialysis patients.
Impact
The acquisition expanded Quest's ability to serve approximately 200,000 dialysis patients annually with laboratory and water purity testing. Quest also entered a services agreement to provide comprehensive dialysis-related testing for Fresenius-operated centers.
Outcome
The acquisition strengthened Quest's position in chronic kidney disease diagnostics, a growing market given the prevalence of diabetes and hypertension that drive kidney disease.